Trials / Completed
CompletedNCT00289016
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- BioVex Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talimogene Laherparepvec | Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2008-12-01
- Completion
- 2009-05-01
- First posted
- 2006-02-09
- Last updated
- 2015-12-18
- Results posted
- 2015-12-18
Locations
8 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00289016. Inclusion in this directory is not an endorsement.